<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562831</url>
  </required_header>
  <id_info>
    <org_study_id>98955</org_study_id>
    <nct_id>NCT04562831</nct_id>
  </id_info>
  <brief_title>The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.</brief_title>
  <official_title>A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elysium Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous&#xD;
      system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole,&#xD;
      there is no effective treatment. Care of advanced ALS will have a cost of 4-8 million NOK per&#xD;
      year&#xD;
&#xD;
      Research i.a. from the investigators department has shown that increased activity in histone&#xD;
      deacetylation enzymes (sirtuins) together with increased access to NAD can delay disease&#xD;
      progression. Nicotinamide riboside (NR) can increase cells' access to NAD and Pterostilben&#xD;
      will stimulate sirtuins.&#xD;
&#xD;
      The investigators want to study whether combination therapy with NR and Pterostilben can&#xD;
      inhibit neurodegeneration in ALS and thereby delay disease development, increase survival and&#xD;
      improve quality of life in ALS.&#xD;
&#xD;
      In the study, the investigators will use 2 different dosages on the active treatment and&#xD;
      strength calculations show that 180 patients are needed to show a rather weak effect.&#xD;
      Patients will be recruited in collaboration with hospitals in Helse Vest, AHUS, Drammen, OUS&#xD;
      and St. Olavs hospital.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression as assessed by Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)</measure>
    <time_frame>Change from baseline to 1 year</time_frame>
    <description>ALSFRS-R is a validated rating instrument for monitoring the progression of disability in patients with ALS. The minimum score is 0 and the maximum score is 48, the higher score the more function is retained.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vital capacity</measure>
    <time_frame>Change from baseline to 1 year</time_frame>
    <description>Vital capacity in sitting position and supine by spirometry. Spirometry measures the amount of air that can be inhaled or exhaled and vital capacity is the volume of air breathed out after the deepest inhalation, the higher value the better vital capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive functions as assessed by the Edinburgh Cognitive Scale (ECAS)</measure>
    <time_frame>Change from baseline to 1 year</time_frame>
    <description>ECAS determines cognitive and behavioural changes of patients suffering from ALS. The minimum score is 0 and the maximum score is 136, the lower the score the greater the deficit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Neurofilament light chain (NFL) levels in serum</measure>
    <time_frame>Change from baseline to 1 year</time_frame>
    <description>NFL levels in serum, baseline values and changes during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as assessed by the quality of life questionnaire SF-36</measure>
    <time_frame>Change from baseline to 1 year</time_frame>
    <description>SF-36 is a 36-item patient-reported survey of patient health. The minimum score is 0 and the maximum score is 100. The higher the score the less disability.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through study completion, 1 year</time_frame>
    <description>Survival of patients through the study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Newly diagnosed ALS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)&#xD;
Single dose EH301 (1000mg Nicotinamide riboside / 200mg Pterostilbene)&#xD;
Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Earlier diagnosed ALS patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose EH301 (1500mg Nicotinamide riboside / 300mg Pterostilbene)&#xD;
Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EH301 (Nicotinamide Riboside/Pterostilbene)</intervention_name>
    <description>Comparison of 2 different dosages with placebo in newly diagnosed ALS patients and comparison of high dose with placebo in earlier ALS patients.</description>
    <arm_group_label>Earlier diagnosed ALS patients</arm_group_label>
    <arm_group_label>Newly diagnosed ALS patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Arm 1 (newly diagnosed ALS patients)&#xD;
&#xD;
          -  Have a clinical diagnosis of probable ALS according to the revised El Escorial&#xD;
             criteria.&#xD;
&#xD;
          -  MR of the brain and cervical spine cannot explain symptoms.&#xD;
&#xD;
          -  Diagnosed with likely ALS within 6 months from enrolment and treated with Riluzole&#xD;
             50mg x 2&#xD;
&#xD;
          -  Symptom onset no longer than 2 year prior to inclusion.&#xD;
&#xD;
          -  ALS-FRC-R of 36 or more (not any item below 2).&#xD;
&#xD;
          -  Age equal to or greater than 35 years at time of enrollment&#xD;
&#xD;
        Arm 2 (earlier diagnosed ALS patients)&#xD;
&#xD;
          -  Have a clinical diagnosis of probable ALS according to the revised El Escorial&#xD;
             criteria.&#xD;
&#xD;
          -  MR of the brain and cervical spine cannot explain symptoms.&#xD;
&#xD;
          -  Treated with Riluzole 50mg x 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia, FTD or other neurodegenerative disorder at baseline visit&#xD;
&#xD;
          -  Any psychiatric disorder that would interfere with compliance in the study.&#xD;
&#xD;
          -  Use of high dose vitamin B3 supplementation within 30 days of enrollment&#xD;
&#xD;
          -  Metabolic, neoplastic, or other physically or mentally debilitating disorder at&#xD;
             baseline visit.&#xD;
&#xD;
          -  Genetically confirmed mitochondrial disease&#xD;
&#xD;
          -  Patients who become tracheostomized as part of the treatment of ALS&#xD;
&#xD;
          -  Patients with short expected survival at the discretion of the investigator. Such&#xD;
             cases cannot be expected to follow protocol procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole-Bjørn Tysnes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ole-Bjørn Tysnes</last_name>
    <phone>+4755975063</phone>
    <email>obty@haukeland.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole-Bjørn Tysnes</last_name>
    </contact>
    <investigator>
      <last_name>Ole-Bjørn Tysnes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vestre Viken HF</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Kristine Bjørnå</last_name>
    </contact>
    <investigator>
      <last_name>Ingrid Kristine Bjørnå</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Førde HF</name>
      <address>
        <city>Førde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Lif Breivik</last_name>
    </contact>
    <investigator>
      <last_name>Kristin Lif Breivik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Fonna HF</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ineke HogenEsch</last_name>
    </contact>
    <investigator>
      <last_name>Ineke HogenEsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Nakken</last_name>
    </contact>
    <investigator>
      <last_name>Ola Nakken</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelina Maniaol</last_name>
    </contact>
    <investigator>
      <last_name>Angelina Maniaol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Ruth Schlüter</last_name>
    </contact>
    <investigator>
      <last_name>Katrin Ruth Schlüter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset Nord-Norge</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margitta Kampmann</last_name>
    </contact>
    <investigator>
      <last_name>Margitta Kampmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St.Olavs Hospital HF</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrid Botne Sando</last_name>
    </contact>
    <investigator>
      <last_name>Sigrid Botne Sando</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

